Angiogenesis Inhibitor Development Services for Brain Tumors

Angiogenesis is the growth of new capillaries from pre-existing vessels and is a complex process involving the proliferation, migration, and differentiation of vascular endothelial cells (ECs) in response to specific signaling stimuli. Glioblastoma (GBM) in brain tumors is a highly vascularized tumor and glioma growth is dependent on the formation of new blood vessels.

Figure 1. Schematic representation of angiogenic events in GBM. (Ahir, B. K., et al., 2020)

Brain tumor progression is closely related to neointima formation, and vascular endothelial growth factor (VEGF) plays a major role in neovascularization. The formation of new blood vessels is stimulated by a VEGF-driven process, so VEGF may be an important therapeutic target.

We offer drug development services targeting angiogenesis for brain tumor

Alfa Cytology focuses on anti-angiogenic therapies, and we provide targeted brain tumor drug development services targeting angiogenesis, particularly VEGF, to inhibit the proliferation of brain tumors, including GBM, by inhibiting the formation of new tumors blood vessels using angiogenesis inhibitors and drugs.

Drug development services

VEGF signaling mediates multiple functions, including pro-angiogenic activity, vascular permeability activity, and stimulation of endothelial cell migration. VEGF plays an important role in the survival and proliferation of gliomas. Anti-VEGF drugs are effective in inhibiting neovascularization and promoting the regression of existing neovascularization.

Taking the VEGF target as an example, Alfa Cytology has a full range of human anti-VEGF antibodies and can provide humanized monoclonal antibodies and anti-VEGF/VEGFR fusion protein development services against VEGF. Compared to small molecule drugs, the stability of VEGF targeting drug development is relatively high.

Preparation of humanized anti-VEGF antibodies

High affinity human anti-VEGF single-chain antibody obtained from phage human antibody library screening
Construction of eukaryotic expression vector for the human anti-VEGF complete antibody molecule
Expression of human anti-VEGF complete antibody molecules in CHO cells
Purification of human-derived anti-VEGF antibody molecules

The preparation process of human anti-VEGF antibody

The preparation process of human anti-VEGF antibody - Alfa Cytology

In addition, we also provide VEGF antibody affinity assay service, VEGF antibody inhibition of HUVEC cell proliferation assay service, and VEGF antibody in vivo tumor growth inhibition assay service.

Other targets that can be developed

Target	Function
Basic fibroblast growth factor (bFGF)	Present both in tumor cells and in the vascular basement membrane for sustained release and upregulation during angiogenesis.
Fibroblast growth factor receptor (FGFR)	FGFR regulates a range of angiogenic processes.
Hepatocyte growth factor/dispersion factor (HGF/SF)	HGF/SF is a heparin-binding mesenchymal-derived cytokine that regulates angiogenesis by both upregulating VEGF and inhibiting platelet response protein 1 (TSP-1).
Platelet-derived growth factor (PDGF)	PDGF proteins regulate angiogenesis by binding to and activating two cell surface receptor tyrosine kinase (RTK) receptors, PDGFR-α and PDGFR-β.
TGF-β	High levels of TGF-β are associated with poor prognosis in GBM and enhance the expression of several pro-angiogenic factors, such as VEGF, FGF, and PDGF-β.
Matrix metalloproteinases (MMP)	MMP selectively degrades components of the ECM and is associated with tumor cell invasion angiogenesis and inhibition of antitumor immune surveillance.
Angiopoietins (Angs)	Angs induce environment-dependent pro-angiogenic or anti-angiogenic effects.

Alfa Cytology offers brain tumor drug development services targeting angiogenesis, please contact us for the latest proposals. We look forward to working with you on the development of targeted brain tumor drugs targeting angiogenesis.

Reference

Ahir, B. K., et al. (2020). "Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma." Molecular Neurobiology, 57(5): 2461-2478.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.